Neurocrine Biosciences Inc. (NASDAQ:NBIX) reported fourth-quarter adjusted EPS of $1.69, higher than the $1.54 reported a ...

Neurocrine Biosciences, Inc.’s NBIX share price has dipped by 18.53%, which has investors questioning if this is right time ...

Q4 2024 Earnings Call Transcript February 6, 2025 Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS ...

Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while ...

Neurocrine Biosciences Inc (NBIX) reports robust sales growth and strategic investments amid competitive pressures and payer challenges.

Neurocrine Biosciences, Inc. ( NASDAQ: NBIX) Q4 2024 Earnings Conference Call February 6, 2025 4:30 PM ET Todd Tushla - Vice President of Investor Relations Kyle Gano - Chief Executive Officer Matt ...

Learn more about whether Biogen Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Evercore ISI analyst Cory Kasimov maintained a Buy rating on Neurocrine (NBIX – Research Report) on January 31 and set a price target of ...

市值154亿美元的生物制药公司Neurocrine Biosciences Inc. (NASDAQ: NBIX )年初至今取得了11.7%的亮眼回报。根据提交给证券交易委员会的文件显示，公司首席财务官Matt ...

根据最新的SEC文件显示，Neurocrine Biosciences Inc. (NASDAQ: NBIX )的首席医疗官Eiry ...